Abstract
In addition to the classical neurotransmitters, neuropeptides represent an important class of modulators for affective behaviors and associated disorders, such as anxiety disorders. Many neuropeptides are abundantly expressed in brain regions involved in emotional processing and anxiety behaviors. Moreover, risk factors for anxiety disorders such as stress modulate the expression of various neuropeptides in the brain. Due to the high prevalence of anxiety disorders and yet limited treatment options, there is a clear need for more effective therapeutics. In this regard, the various neuropeptides represent exciting candidates for new therapeutic designs. In this review, I will provide an up-to-date summary on the evidences for the involvement of seven neuropeptides in anxiety: corticotropin-releasing factor, urocortins, vasopressin, oxytocin, substance P, neuropeptide Y and galanin. This review will cover the behavioral effects of these neuropeptides in animal models of anxiety by both genetic and pharmacological manipulations. Human studies indicating a role for these neuropeptides in anxiety disorders will also be discussed.
Keywords: Anxiety, neuropeptides, stress, corticotropin-releasing factor, urocortin, vasopressin, oxytocin, substance P, neuropeptide Y, galanin
Current Pharmaceutical Design
Title:Neuropeptides as Therapeutic Targets in Anxiety Disorders
Volume: 18 Issue: 35
Author(s): En-Ju D. Lin
Affiliation:
Keywords: Anxiety, neuropeptides, stress, corticotropin-releasing factor, urocortin, vasopressin, oxytocin, substance P, neuropeptide Y, galanin
Abstract: In addition to the classical neurotransmitters, neuropeptides represent an important class of modulators for affective behaviors and associated disorders, such as anxiety disorders. Many neuropeptides are abundantly expressed in brain regions involved in emotional processing and anxiety behaviors. Moreover, risk factors for anxiety disorders such as stress modulate the expression of various neuropeptides in the brain. Due to the high prevalence of anxiety disorders and yet limited treatment options, there is a clear need for more effective therapeutics. In this regard, the various neuropeptides represent exciting candidates for new therapeutic designs. In this review, I will provide an up-to-date summary on the evidences for the involvement of seven neuropeptides in anxiety: corticotropin-releasing factor, urocortins, vasopressin, oxytocin, substance P, neuropeptide Y and galanin. This review will cover the behavioral effects of these neuropeptides in animal models of anxiety by both genetic and pharmacological manipulations. Human studies indicating a role for these neuropeptides in anxiety disorders will also be discussed.
Export Options
About this article
Cite this article as:
D. Lin En-Ju, Neuropeptides as Therapeutic Targets in Anxiety Disorders, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530871
DOI https://dx.doi.org/10.2174/138161212803530871 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry Renin-Angiotensin System and Alzheimer’s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives
Protein & Peptide Letters Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Biomarkers of Acute Kidney Injury in Critical Care Medicine: A Literature Review Based on Recent Patent Applications
Recent Patents on Biomarkers New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Retinal Vascular Features for Cardio Vascular Disease Prediction: A Review
Recent Patents on Computer Science Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Management of COVID-19 very Elderly Patients in Nursing Homes and Long-Term Care Facilities: Description of a New Model and Experience in a Medicalized Nursing Home
Coronaviruses